Saudi Arabia Biosurgery Market Overview, 2031

Key Insights

• The Saudi Arabia biosurgery market represents one of the fastest-growing and most strategically significant national markets for surgical biomaterials in the Middle East region. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.
• The Saudi Arabia biosurgery market is distinguished by its ambitious healthcare transformation under Vision 2030, world-class infrastructure development, and rapidly expanding surgical volumes. Healthcare expenditure in the Kingdom exceeded SAR 190 billion in 2025, representing approximately 7% of GDP, with per capita health spending reaching approximately $1,500 to $1,800. The healthcare market exceeds USD 40 billion annually and is growing at 5-7% per year. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and the Health Sector Transformation Program (HSTP) under Vision 2030.
• Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of robotic-assisted and minimally invasive surgical techniques. King Abdullah Medical City in Makkah performed the fastest launch of robotic surgeries in the Middle East in 2025, with 52 oncological gynecological surgeries. Saudi Arabia's growing elderly population represents a significant demand driver. As of 2025, 1.7 million people (4.8% of the population) were aged 60 years or older. The population aged 65 and above reached 1.13 million in 2025, representing an 8.5% year-over-year increase.
• The regulatory environment, centered on the Saudi Food and Drug Authority (SFDA), plays a decisive role in shaping market dynamics. The SFDA has evaluated 295 clinical studies for medical devices, approving 157 with 84 currently active across the Kingdom. In August 2025, the SFDA published MDS-G27, comprehensive guidance on digital health products.
Market Outlook
• According to the research report, "Saudi Arabia Biosurgery Market Overview, 2031 Overview, 2031," published by Bonafide Research, the Saudi Arabia Biosurgery market is anticipated to add to more than USD 34 Million by 2026–31.
• The Saudi biosurgery market is expected to maintain robust growth through 2031, supported by ambitious healthcare transformation, favorable demographic trends, ongoing technological innovation, and the Kingdom's strategic position as a regional healthcare hub. Saudi Arabia's healthcare expenditure continues to rise significantly, exceeding SAR 190 billion in 2025, representing approximately 7% of GDP. The healthcare market exceeds USD 40 billion annually and is growing at 5-7% per year. Healthcare investments announced during the Global Health Exhibition 2025 exceeded 133 billion Saudi riyals.
• The growing elderly population represents a significant long-term demand driver. As of 2025, 1.7 million people (4.8% of the population) were aged 60 years or older. The population aged 65 and above reached 1.13 million in 2025, growing at 8.5% year-over-year. Life expectancy in the Kingdom has risen to 79.7 years, underscoring the demographic shift toward an aging population. Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. King Abdullah Medical City in Makkah performed the fastest launch of robotic surgeries in the Middle East in 2025. The Kingdom is rapidly becoming a regional hub for robotic and minimally invasive surgical techniques, creating new opportunities for advanced biosurgical products.
• Expanding surgical volumes are a key driver propelling market expansion. King Saud Medical City alone performed over 25,000 surgical procedures in 2025, representing 20% growth compared to 2024. King Salman Hospital performed 9,735 surgical procedures in 2025, recording 19% growth. The Riyadh Third Health Cluster delivered surgical services to over 61,000 patients in 2025..

Market Dynamics



Driver: Ambitious Healthcare Transformation Under Vision 2030
The Saudi Arabia biosurgery market is experiencing unprecedented growth driven by the Kingdom's Vision 2030 healthcare transformation. The Health Sector Transformation Program (HSTP) is designed to build an integrated, efficient, and high-quality healthcare system. Healthcare investments announced during the Global Health Exhibition 2025 exceeded 133 billion Saudi riyals. The Ministry of Health signed more than 124 strategic agreements on the opening day of the Global Health Exhibition 2025. The Kingdom's surgical capacity has expanded dramatically, with weekly operations rising from 6,000 to 12,000. Waiting times for surgical procedures have been reduced from 70 days to 24 days. The private sector's share of healthcare spending is targeted to increase from 25% to 35%. These transformations are directly driving demand for biosurgical products across all categories.

Challenge: Regulatory Complexity and Infrastructure Constraints
Despite the market's growth potential, biosurgery manufacturers face challenges from regulatory complexity and infrastructure constraints. The SFDA's regulatory framework, while modernizing, requires compliance with the Medical Devices Law issued by Royal Decree No. (M/54). Medical device marketing authorization requires adherence to quality management system requirements. Additionally, hospital bed density stands at 2.34 per 1,000 population in 2025, ranking 68th globally. While the Kingdom has made significant progress adding 1,700 government hospital beds and 2,900 private sector beds capacity constraints persist. The rapid expansion of healthcare infrastructure requires continued investment in surgical workforce development and hospital capacity to meet growing demand.

Trend: Accelerating Adoption of Robotic-Assisted and Minimally Invasive Surgery
The Saudi biosurgery market is experiencing a significant trend toward robotic-assisted and minimally invasive surgical techniques. King Abdullah Medical City in Makkah performed the fastest launch of robotic surgeries in the Middle East in 2025. Since May 2025, the facility has performed 52 robotic oncological gynecological surgeries (May 26, 2025), 23 robotic chest surgeries (May 19, 2025), 20 robotic urological surgeries (July 1, 2025), and 3 robotic heart surgeries. In 2024, King Faisal Specialist Hospital and Research Centre achieved a milestone by performing the first robotic-assisted kidney transplant in the Kingdom. The King Faisal Medical Complex in Taif performed the first two robotic surgeries using the Da Vinci system in May 2025. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for robotic and minimally invasive applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand.

Policies

• The Saudi Food and Drug Authority (SFDA) serves as the primary regulatory authority for medical devices in Saudi Arabia. The SFDA has evaluated 295 clinical studies for medical devices, approving 157, with 84 currently active.
• The Medical Devices Law, issued by Royal Decree No. (M/54) dated 06/07/1442 H, establishes the regulatory framework for medical devices in the Kingdom. All manufacturers must adhere to quality management system requirements.
• MDS-G27 (Guidance on Digital Health Products) was published on August 11, 2025 (Version 1.0), providing comprehensive guidance covering Software as a Medical Device (SaMD), AI/ML-enabled diagnostics, and other digital health products.
• SFDA marketing authorization requires medical devices to undergo rigorous review. In 2025, the SFDA approved a medical device using advanced deep brain stimulation technology.
• Medical device clinical studies are regulated by the SFDA. The Authority has established a framework for evaluating and approving clinical investigations of medical devices in the Kingdom.
• The Health Sector Transformation Program (HSTP), one of the flagship programs under Vision 2030, aims to build an integrated, efficient, and high-quality healthcare system. The program targets increasing private sector participation in healthcare to 32% by 2030.

Segment Analysis

Saudi Arabia Biosurgery Market By Product
• Bone-Graft Substitutes represent the largest product category within the Saudi biosurgery market, driven by the high volume of orthopedic and spinal procedures. Saudi Arabia's growing elderly population with 1.7 million people aged 60 and over continues to drive demand for musculoskeletal interventions. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The Kingdom's expanding surgical capacity, with weekly operations rising from 6,000 to 12,000, supports sustained demand for bone-graft substitutes.
• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. With King Saud Medical City alone performing over 25,000 surgical procedures in 2025 and the Riyadh Third Health Cluster serving over 61,000 patients, demand for hemostatic products is substantial and growing.
• Surgical Sealants and Adhesives represent the fastest-growing product category in the Saudi biosurgery market, driven by increasing adoption of robotic-assisted and minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The rapid expansion of robotic surgery, with King Abdullah Medical City performing the fastest launch of robotic surgeries in the Middle East, supports the growth of this segment.
• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial. Robotic oncological gynecological surgeries represent a growing application area.
• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in Saudi hospitals. King Saud Medical City's over 25,000 surgical procedures in 2025 included a wide range of routine and emergency cases.
• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines. Robotic chest surgeries (23 cases at King Abdullah Medical City) and colorectal procedures reflect the growing volume of thoracic and gastrointestinal procedures, supporting steady demand for these products.

Saudi Arabia Biosurgery Market By Application • Orthopedic Surgery is the largest application area for biosurgical products in Saudi Arabia, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures. Saudi Arabia's growing elderly population with 1.7 million people aged 60 and over continues to drive demand for musculoskeletal interventions. The Kingdom's expanding surgical capacity supports sustained growth in orthopedic procedures.
• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. King Saud Medical City performed over 25,000 surgical procedures in 2025, including a wide range of routine and emergency cases.
• Cardiovascular Surgery represents the fastest-growing application area in the Saudi biosurgery market, driven by the high prevalence of cardiovascular disease and the aging population. King Abdullah Medical City performed 3 robotic heart surgeries. The health system also performed 16 open-heart surgeries and 204 cardiac catheterizations for Hajj pilgrims. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures.
• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.
• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery.
• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system. Robotic oncological gynecological surgeries represented 52 cases at King Abdullah Medical City, the largest share of robotic procedures. Products used include hemostatic agents, adhesion barriers, and surgical sealants.
• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system. King Abdullah Medical City performed 20 robotic urological surgeries. Products are used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.
• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS). King Abdullah Medical City performed 23 robotic chest surgeries. The rising burden of lung cancer and other thoracic conditions supports demand in this specialty.

Saudi Arabia Biosurgery Market By Source/Origin
• Biologic products represent the largest source category in the Saudi biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The SFDA's rigorous requirements for medical devices ensure high safety standards for biological materials.
• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Saudi market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The Saudi healthcare system's emphasis on efficiency and advanced technology, coupled with Vision 2030's focus on localization, favors synthetic alternatives for certain applications.

Saudi Arabia Biosurgery Market By End-User
• Hospitals remain the largest end-user segment for biosurgical products in Saudi Arabia, accounting for the majority of revenue. The Kingdom has 2.34 hospital beds per 1,000 population in 2025, with 1,700 government beds and 2,900 private beds added. King Saud Medical City performed over 25,000 surgical procedures in 2025. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization.
• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Saudi biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity, supported by private sector participation targets under Vision 2030, supports the adoption of biosurgical products in these settings.
• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.

Saudi Arabia Biosurgery Market Economics

• Saudi Arabia’s biosurgery market benefits from high government healthcare investment, rising private-sector participation, and Vision 2030 reforms. Healthcare expenditure exceeded SAR 190 billion (around 7% of GDP) in 2025, while the healthcare market exceeds USD 40 billion annually. Private-sector participation is targeted to increase healthcare spending share from 25% to 35%. Manufacturers must navigate public tenders and an increasingly important private healthcare market.
• Healthcare infrastructure is expanding rapidly, with 2.34 hospital beds per 1,000 population. In 2025, approximately 1,700 government and 2,900 private-sector beds were added, while major projects in Riyadh expanded capacity by more than 3,000 beds. Surgical capacity has also improved, with weekly operations increasing from 6,000 to 12,000 and average waiting times falling from 70 to 24 days. These developments support rising demand for biosurgical products.
• Investment and innovation are strongly supported by Vision 2030 and the Health Sector Transformation Program. Healthcare investments announced at the Global Health Exhibition 2025 exceeded SAR 133 billion, with more than 124 strategic agreements. Robotic and minimally invasive surgery are expanding rapidly, including robotic oncology, urology, thoracic, cardiac, and transplant procedures. This technological shift creates opportunities for advanced biosurgical products designed for robotic and minimally invasive applications.
• Saudi Arabia’s long-term biosurgery outlook remains highly positive, supported by healthcare transformation, infrastructure expansion, ageing, and technology adoption. Life expectancy has reached 79.7 years, while 1.7 million people aged 60 and older represent approximately 4.8% of the population. The SFDA provides the central regulatory framework for medical devices and is modernizing approval processes. The biosurgery market is expected to add more than USD 34 million during 2026–2031, creating significant opportunities for manufacturers with strong regulatory and local partnerships.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Biosurgery Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Bone-Graft Substitutes
• Hemostatic Agents
• Surgical Sealants & Adhesives
• Adhesion Barriers
• Soft-Tissue Attachments
• Staple-Line Reinforcement

By Application:
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Urological Surgery
• Other surgeries (Thoracic surgeries & more)

By Source/Origin
• Biologic
• Synthetic / Semi-synthetic

By End-user:
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others